Robert E. Gagnon
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Harvard Bioscience Forms Scientific Advisory Board. Harvard Bioscience announced the creation of a Scientific Advisory Board. This move is intended to support the company's scientific direction and product development. The stock is currently trading with a high beta, indicating higher volatility relative to the broader market.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.
Transaction History
| IRD | ▼ Sell | Open Market | 28,000 | $127K | 9/3/2026 | View on chart |
| IRD | ▼ Sell | Open Market | 7,783 | $23K | 7/23/2026 | View on chart |
| HBIO | ▲ Buy | Grant | 16,556 | $0 | 6/9/2026 | View on chart |
| IRD | ▼ Sell | Open Market | 7,842 | $41K | 4/23/2026 | View on chart |
| IRD | ▲ Buy | Grant | 400,000 | $0 | 1/22/2026 | View on chart |
| VSTM | ▼ Sell | Open Market | 283 | $3K | 12/16/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 281 | $3K | 9/16/2025 | View on chart |
| IRD | ▲ Buy | Grant | 200,000 | $0 | 9/10/2025 | View on chart |
| HBIO | ▲ Buy | Grant | 110,000 | $0 | 7/16/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 284 | $2K | 6/16/2025 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 5/22/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 284 | $2K | 3/17/2025 | View on chart |
| VSTM | ▼ Sell | Open Market | 130 | $568 | 12/19/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 285 | $1K | 12/16/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 131 | $365 | 9/19/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 287 | $804 | 9/16/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 131 | $421 | 6/20/2024 | View on chart |
| VSTM | ▲ Buy | Grant | 8,333 | $0 | 6/18/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 283 | $988 | 6/17/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 130 | $1K | 3/19/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 283 | $3K | 3/18/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 9,204 | $126K | 2/6/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 9,204 | $101K | 1/12/2024 | View on chart |
| VSTM | ▼ Sell | Open Market | 130 | $1K | 12/19/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 284 | $2K | 12/18/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 130 | $1K | 9/19/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 278 | $3K | 9/18/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 130 | $1K | 6/20/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 283 | $3K | 6/16/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,664 | $716 | 3/20/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 3,654 | $1K | 3/16/2023 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,429 | $529 | 12/19/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 12,408 | $5K | 12/16/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,348 | $2K | 9/19/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,351 | $2K | 6/21/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 16,627 | $17K | 5/16/2022 | View on chart |
| VSTM | ▲ Buy | Grant | 50,000 | $0 | 5/14/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 1,409 | $2K | 3/21/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 19,612 | $40K | 1/3/2022 | View on chart |
| VSTM | ▼ Sell | Open Market | 5,497 | $12K | 12/20/2021 | View on chart |
| VSTM | ▲ Buy | Grant | 148,500 | $0 | 12/15/2021 | View on chart |
| VSTM | ▼ Sell | Tax Withholding | 45,329 | $130K | 8/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026
Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.